Generic drug maker QLT Inc. has been dealt yet another blow in its effort to maintain its presence in the market for prostate cancer treatments, with a federal judge issuing a damaging injunction and setting the stage for a drawn-out appeal.
In a dramatic turnaround, a district judge has reversed a $51 million jury award to medical device maker Medtronic Navigation Inc., deciding after four months that its rival did not infringe the company’s patents for image-guided surgical techniques.
Under India’s new patent laws allowing public opposition to patent grants, a Bangalore-based public interest group is preparing to file a pre-grant opposition to Roche’s Tamiflu, one of two drugs used to treat avian influenza.
The Securities and Exchange Commission has asked a district court to allow the agency to distribute the $250 million settlement reached with Qwest Communications to shareholders through a private distribution agent rather than through the SEC’s own Fair Fund system.
Generic pharmaceutical company Apotex Inc. has received a boost from a federal appeals court in its ongoing patent dispute with drug maker GlaxoSmithKline Plc. involving the widely-used antidepressant drug Paxil.
The Regents of the University of California are walking away with a big win for their intellectual property, with chemical firm Monsanto Co. handing over $100 million to end a patent infringement lawsuit over a hormone for dairy cows.
A surprisingly early approval by U.S. regulators of a generic version of allergy treatment Flonase prompted GlaxoSmithKline Plc to rush to the courthouse this week, securing a restraining order that in effect also stopped shipments of its own authorized generic version.
Although Lerner, David, Littenberg, Krumholz & Mentlik has focused solely on intellectual property litigation since opening its doors over 30 years ago, the firm may be gearing up for its biggest case yet. Lerner David will represent Sony in a patent dispute against Kodak that involves 43 different patents and has wide-ranging implications for the industry.
Resolving all but one of the company’s patent-related disputes, molecular diagnostics company Third Wave Technologies Inc. has dismissed without prejudice its suit against rivals Chiron Corp. and Bayer Corp. over technology related to the hepatitis C virus, or HCV.
Canada’s largest pharmaceutical company, Biovail Corporation, has filed a $4.6 billion lawsuit against 22 institutional and individual investors, alleging that powerful hedge funds conspired with Wall Street analysts in a plot to drive down the company’s shares.
Takeda Pharmaceutical Company has prevailed in a patent infringement suit filed three years ago against three generic drug makers after a judge upheld the patent covering the key ingredient in the company’s blockbuster diabetes treatment ACTOS.
Struggling to determine if any wrongdoing occurred on U.S. soil, the U.S. Securities and Exchange Commission is pressing onward with its own investigation into the scandal surrounding the United Nations’ Iraq Oil-for-Food program, issuing its latest subpoena to Italian auto giant, Fiat SpA.
In an attempt to keep a former partner from sinking its teeth into the $5 billion global coronary stent market, Israel’s Medinol Ltd. filed a new legal claim Monday against Boston Scientific Corp. that alleges its stents violate three of Medinol’s patents.
Biotechnology company MedImmune Inc. gained another chance to fight off rival Genentech Inc. this week, with the U.S. Supreme Court agreeing to hear the previously dismissed case centering on whether a company must refuse to pay royalties before challenging a patent claim.
Already tangled up in the scandal surrounding the United Nations’ Oil-for-Food program in Iraq, Danish pharmaceutical giant Novo Nordisk A/S has now been subpoenaed by the U.S. Securities and Exchange Commission to produce documents detailing its involvement in the program.
Charged once again with violating U.S. competition law, pharmaceutical giant AstraZeneca stands accused of illegally trying to prevent generic versions of its blockbuster heart drug Toprol-XL from entering the marketplace, in a lawsuit filed recently by a pension fund.
Yet another scientist has accused medical device maker Medtronic Inc. of abusing intellectual property rights, the latest in a series of lawsuits filed against the company after it agreed to pay $1.4 billion to a Los Angeles surgeon last year.
Israeli generics maker Teva Pharmaceutical Industries Ltd. fired off a lawsuit Friday in an attempt to counter claims that it had violated patent laws regarding the production of a popular antibiotic called azithromycin—a generic version of the Pfizer Inc.-developed drug Zithromax.
Pharmaceutical company AstraZeneca PLC is appealing a federal court ruling that scuttled its patents for the valuable heart drug Toprol-XL and threatened its pipeline of branded drugs.
With millions of U.S. anti-terror funding in the balance, smallpox vaccine maker Bavarian-Nordic has sued rival drug maker Acambis Inc. for patent infringement in Austria with an eye to shutting down its manufacturing plant there.